Highbridge Capital Management disclosed a 5.3% brand new stake in medical research company Protalix Biotherapeutics Inc. (NYSE:PLX). PLX lost a $1.3 million investment by Kevin Kotler’s Broadfin Capital during the third quarter so this new $2 million position by Highbridge Capital is a welcome development. The details of Highbridge’s disclosure can be seen below.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Highbridge Capital Management | 0 | 6,523,399 | 0 | 6,523,399 | 6,523,399 | 5.3% |
Follow Glenn Russell Dubin's Highbridge Capital Management
Page 1 of 6 – SEC Filing
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| SCHEDULE 13G | |
| Under the Securities Exchange Act of 1934 | |
| (Amendment No. )* | |
| Protalix | |
| (Name of Issuer) | |
| Common Stock, | |
| (Title of Class of Securities) | |
| 74365A101 | |
| (CUSIP Number) | |
| December | |
| (Date of event which requires filing of this statement) | |
| Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed: | |
| ¨ | Rule 13d-1(b) |
| x | Rule 13d-1(c) |
| ¨ | Rule 13d-1(d) |
| (Page 1 of 6 Pages) | |
______________________________
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act“) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes)
